VISION To create breakthrough drugs that address the unmet medical needs of patients.
STRATEGY We will use our world class Research and Development capabilities to produce a broad portfolio of IND-ready and clinical phase small molecule assets, and will deliver value to shareholders via a strategic transaction.
CORE VALUES Efficiency: We demand efficiency from both ourselves and our partners
Quality-Speed Balance: We effectively balance quality and speed to produce timely, best-in-class drug candidates
Nimbleness: We dance around our less agile competition, consistently leapfrogging them.